Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Afatinib is one of the standard treatments for patients with epidermal growth factor receptor (EGFR)- mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (PS ≥ 2) are limited. This study aimed to retrospectively review the clinical outcomes and safety of afatinib treatment in EGFR-mutation-positive (EGFRm+) NSCLC patients with PS ≥ 2. |